

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

### Journal of Affective Disorders



journal homepage: www.elsevier.com/locate/jad

# Psychological health status in postpartum women during COVID-19 pandemic: A systematic review and meta-analysis



Shen Gao<sup>1</sup>, Shaofei Su<sup>1</sup>, Enjie Zhang, Ruixia Liu, Yue Zhang, Chengrong Wang, Jianhui Liu, Shuanghua Xie, Chenghong Yin<sup>\*</sup>, Wentao Yue<sup>\*</sup>

Department of Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, China

ARTICLE INFO	A B S T R A C T
<i>Keywords:</i> Mental health status Prevalence Postpartum women COVID-19 Meta-analysis	<ul> <li>Background: This systematic review and meta-analysis pooled the prevalence of psychological symptoms during the COVID-19 pandemic and examined the effects of the pandemic on psychological health in postpartum women.</li> <li>Methods: A systematic literature search and identification were performed in PubMed, EMBASE, Web of Science, and PsycINFO databases until June 16th, 2021. The fixed or random effect models to estimate the pooled prevalence of postpartum psychological symptoms during the COVID-19 pandemic and the odds ratio (OR) of COVID-19 for psychological symptoms.</li> <li>Results: A total of 29 articles including 20,225 postpartum women during the COVID-19 pandemic and 8312 before the COVID-19 pandemic were identified. During the COVID-19 pandemic, the prevalence of postpartum depressive, anxiety, stress, and post-traumatic stress disorder symptoms were 26.7 % (95 % CI: 22.0–31.9 %), 33.8 % (95 % CI: 21.1–49.4 %), 55.0 % (95%CI: 27.9–79.5 %), and 33.7 % (95%CI: 19.6–51.5 %), respectively. The ORs of COVID-19 pandemic for postpartum depressive and anxiety symptoms were 1.54 (95 % CI: 1.00–2.36) and 2.56 (95%CI: 1.62–4.04). Subgroup analyses revealed that women with &gt;6 weeks after delivery, younger than 35 years old, low income, less education and without breastfeeding experienced a higher risk of depressive or anxiety symptoms after delivery.</li> <li>Limitations: Only a few of prospective studies were included, and significant but inevitable heterogeneities were found in some analyses.</li> <li>Conclusion: A significantly higher proportion of postpartum women were suffered from psychological symptoms during COVID-19 pandemic, particularly in those with &gt;6 weeks after delivery, younger than 35 years old, low income, less education and formula feeding.</li> </ul>

#### 1. Introduction

Postpartum women are considered to be at high risk for psychological disorders, such as depression and anxiety (Cantwell, 2021). A previous review concluded that nearly 20 % of postpartum women suffered from depressive symptoms in the first 3 months after delivery, and around one-third had not recovered beyond the first year after delivery (Howard et al., 2014). A recent meta-analysis indicated the prevalence of anxiety symptoms was 15 % among postpartum women, and anxiety was a common comorbidity of postpartum depressive disorders (Dennis et al., 2017). Maternal psychological disorders are a serious public health concern because they have adverse effects for mothers' health (Abdollahi and Zarghami, 2018) and for babies' behavioral, emotional, and cognitive development (Letourneau et al., 2012; Stein et al., 2014; Lebel et al., 2016; Feldman et al., 2009; Halligan et al., 2007).

Previous studies found that exposure to stressful events, such as pandemics, natural disasters, or adverse life incidents, could increase the risk for psychological disorders, particularly in postpartum women (Guintivano et al., 2018; Liu et al., 2012). The coronavirus disease 2019 (COVID-19) outbreak in 2020 rapidly became a worldwide pandemic, resulting in 239,437,517 confirmed cases and 4,879,235 deaths globally (World Health Organization, n.d.). A survey of >100 researchers reported that nearly 90 % agreed that COVID-19 could not be eliminated completely but would continue to circulate in the global population for

https://doi.org/10.1016/j.jad.2022.08.107 Received 30 December 2021: Received in revis

Received 30 December 2021; Received in revised form 30 May 2022; Accepted 26 August 2022 Available online 7 September 2022 0165-0327/© 2022 Published by Elsevier B.V.

<sup>\*</sup> Corresponding authors at: No. 251 Yaojiayuan Road, Chaoyang District, Beijing, China.

E-mail addresses: yinchh@ccmu.edu.cn (C. Yin), yuewt@ccmu.edu.cn (W. Yue).

<sup>&</sup>lt;sup>1</sup> These authors have contributed equally to this work and share first authorship



Fig. 1. Study selection process flow chart.

years (Phillips, 2021). Given that COVID-19 is a long-term adverse event that affects every aspect of an individual's life, postpartum psychological disorders may be more frequent during the pandemic. Several studies have investigated the effect of COVID-19 on the mental health of postpartum women (Loret de Mola et al., 2021; Pariente et al., 2020; Racine et al., 2021; Silverman et al., 2020). However, these studies yielded conflicting results. To our knowledge, there has been no quantitative synthesis of available results for postpartum women. Although some systematic reviews and meta-analyses focused on the psychological effects of COVID-19 among pregnant women (Fan et al., 2021; Chmielewska et al., 2021; Hessami et al., 2020), evidence in postpartum women is lacking. Therefore, we performed this systematic review and meta-analysis to pool the prevalence for postpartum adverse psychological symptoms during the COVID-19 pandemic and examine the effects of the pandemic on the psychological health in postpartum women. Our results could provide new evidence for the prevention of postpartum psychological disorders.

#### 2. Method

#### 2.1. Search strategy

This review was registered with PROSPERO (CRD42022332382) and conducted based on the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et al., 2000). Two researchers identified relevant studies independently in PubMed, EMBASE, Web of Science, and PsycINFO databases from their inception until June 16th, 2021. The following search strategies were performed: (pregnant OR breastfeeding OR postpartum OR pregnancy OR perinatal) AND (COVID-19 OR coronavirus OR 2019-nCoV OR SARS-CoV-2) AND (mental OR anxiety OR depression OR depressive OR insomnia OR Post-Traumatic OR sleep OR stress OR psychological OR psychology). In addition, other potentially relevant articles from reference lists and reviews were also considered. No language restrictions were applied. Endnote X9 program (Clarivate Analytics, Philadelphia, PA) was used for management of the studies.

#### 2.2. Study selection criteria

A two-step selection program was performed. First, titles and abstracts of relevant studies were screened by two independent researchers. Studies that met the following criteria were excluded in this step: (1) only recruited prenatal women as study participants; (2) did not assess psychological health symptoms during COVID-19 pandemic; (3) qualitative studies; (4) reviews, letters, comments, or study protocols. Afterwards, full texts of studies identified by the first step were reviewed in the second step. An article was excluded in this step if: (1) the data for postpartum women were not reported separately; (2) psychological health symptoms were not screened by validated scales; (3) one reported mean score for psychological health symptoms instead of prevalence. The inconsistencies of the two researchers were resolved by discussing with another researcher.

#### 2.3. Data extraction

Two reviewers independently used a predesigned standardized form to extract data from each included article in accordance with the MOOSE guidelines (Stroup et al., 2000). Relevant information included first author, year of publication, country of study, study design, study periods, sample size, time after delivery, survey method, prevalence of psychological health symptoms, assessment scales, and cut-offs.

#### 2.4. Quality assessment

A 11-item checklist of Agency for Healthcare Research and Quality (AHRQ) was used to assess the methodological quality of included crosssectional and case-control studies independently by two researchers (Rostom et al., 2004). Each item would be rated as "Yes", "No" or "Unclear" and only "Yes" would be awarded 1 point in quality assessment. We considered a study scored over than 8 as a high-quality, 4 to 7

#### Table 1

Sectional Caulemans, 2021Souther (Ireland, Netherlands, and United Kingdom)Cross- sectional (during COVID-19)5134 state3 months (GADT $\geq 10$ )Caulemans, 2020BelgiumCross- sectionalCross- lockdown (during COVID-19)3 M455N.A.Depression (EPDS $\geq 13$ ) and Anxie (GADT $\geq 10$ )Caulemans, 2020BelgiumCross- sectionalCross- lockdown (during COVID-19)3 M455N.A.Depression (EPDS $\geq 13$ ) and Anxie (GADT $\geq 10$ )Caulemans, 2020TurkeyCross- sectional2020/7 (during COVID-19)4-6 weeks covid COVID-19)Depression (EPDS $\geq 13$ ) and Anxie (GADT $\geq 10$ )Guvenc, 2020TurkeyCross- sectional2020/3/10 to 2020/4/138646-12 weeks covid COVID-19)Guvenc, 2020ItalianCross- sectional2020/3/10 to 2020/5/31866 months covid CPIDS $\geq 13$ ), Anxiety (GTAI $\geq 40$ ) and PTSD (PPQ $\geq 19$ ) covid Apring COVID-19)Datacoli, 2020ItalianCross- sectional2020/6/15 to 2020/6/291634 months pepression (EPDS $\geq 13$ ) and Anxie (EFS $\geq 24$ )Spinola, 2020ItalianCross- sectional2020/3/20 to 2020/4/141081 yearDepression (EPDS $\geq 13$ ) and Anxie (EFS $\geq 24$ )Solacoli, 2020ItalianCross- sectional2020/5/11 to 2020/6/291634 months pepression (EPDS $\geq 13$ ) and Anxie (EFS $\geq 24$ )Solacoli, 2020ItalianCross- sectional2020/3/20 to 2020/4/141081 yearDepression (EPDS $\geq 13$ ) and Anxie (GAD7 $\geq 2$ ) <t< th=""><th>First author and Year</th><th>Country</th><th>Study design</th><th>Study periods</th><th>Sample size</th><th>Time after delivery</th><th>Outcomes and assessment scales</th></t<>	First author and Year	Country	Study design	Study periods	Sample size	Time after delivery	Outcomes and assessment scales
Indefaultion         Scoutified (related, Norway), Barbane, Department, Methods, Rulined (and 2)         Crass (and 2)         2020/16 (a 2020/714)         51.4         B math Barbane, Department, Department, DEPA (2) and Ansis (GAV 2 : 10)           Nates, 2020         Tarkay         Crass         Mar a few weeks of 19         NA         - Few weeks of 19         NA         - Few weeks of 19         NA         - Few weeks of 19         - Few method 19         -	Bo, 2021	China			391	1 week	Depression (PHQ9 $\geq$ 5)
Decision 2020RegimCrose (GAU = 10)Area (a worked of a power of a power of (GAU = 10) (GAU = 10)NADepression (DEPS ≥ 13) and Auxid (GAU = 10)arear, 2020JurkeyCone (GAU = 2007)/40 in 2001/4/182124 over a power of (GAU = 10) (GAU = 10)Depression (DEPS ≥ 13) and Auxid (GAU = 10)aineg, 2020JurkeyCone (GAU = 10)2020/7/182124 over a power of (CPS ≥ 10) (GAU = 10)Depression (DEPS ≥ 10) (GAU = 10)aineg, 2020JulkeyCone (GAU = 10)2020/7/182007/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 10)biological, 2020JulkeyCone (GAU = 10)2020/7/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 10)biological, 2020JulkeyCone (GAU = 10)2020/7/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 10)biological, 2020JulkeyCone (GAU = 10)2020/7/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 2007)biological, 2020JulkeyLalainCone (GAU = 2020/7/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 2020)biological, 2020JulkeyLalainCone (GAU = 2020/7/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 2020)biological, 2020JulkeyLalainCone (GAU = 2020/7/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 2020)biological, 2020JulkeyLalainCone (GAU = 2020/7/182 daysDepression (DEPS ≥ 13) and Auxid (GAU = 2020)biological, 2020Cone (GAU		Switzerland, Netherlands, and United	Cross-	2020/6/16 to 2020/7/14	5134	3 months	Depression (EPDS $\geq$ 13) and Anxiet (GAD7 $\geq$ 10)
2020     Index     Section 1     Section 2     Section 2 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
namer, 2020         Index         Cross.         2020/5 to 2020/7 (initing of 22)         4.6 weeds         permessine (PDS ≥ 13)           sing, 2020         Inia         Cross.         2020/47.0 to 2020/47.0         He         - 12 weeds         permessine (PDS ≥ 10)           sing, 2020         Inia         Cross.         2020/71 to 2020/67.0         He         6 months         permessine (PDS ≥ 10)           sectional         Gauss         2020/67 to 3020/67.20         Ho         6 months         Depressine (PDS ≥ 13)         and PDS > 100, Particle 39           2020         Inian         Cross         2020/67 to 3020/67.20         10 months         Depressine (PDS ≥ 13)         and Anticle 30, 200 months           pinolo, 2020         Inian         Cross         2020/67 to 3020/74         108         1 year         Depressine (PDS ≥ 10)           sectional         Gause 200/72 to 3020/74         108         1 year         Depressine (PDS ≥ 10)           sectional         Cross         2020/74 to 3020/71         29         N.A         Depressine (PDS ≥ 10)           sectional         Cross         2020/74 to 3020/71         29         N.A         Depressine (PDS ≥ 10)           sectional         Cross         2020/74 to 3020/71         1         weeds         Depressine (PDS ≥		Belgium		lockdown (during COVID-	3445	N.A.	-
<table-container>          Jamp, 200         <thjam, 200<="" th=""> <thjam, 200<="" th=""> <thja< td=""><td>Guvenc, 2020</td><td>Turkey</td><td></td><td>2020/5 to 2020/7 (during</td><td>212</td><td>4-6 weeks</td><td>Depression (EPDS <math>\geq</math>13)</td></thja<></thjam,></thjam,></table-container>	Guvenc, 2020	Turkey		2020/5 to 2020/7 (during	212	4-6 weeks	Depression (EPDS $\geq$ 13)
Jakar, 2009     Isalian     Conse, constraint (Conse, constraint)     Stational (Conse, constraint)	Liang, 2020	China	Cross-	2020/3/30 to 2020/4/13	864	6-12 weeks	Depression (EPDS $\geq$ 10)
Jacobis Jacob	Molgora, 2020	Italian	Cross-	2020/3/1 to 2020/5/3	186	6 months	Depression (EPDS $\geq$ 13), Anxiety (STAI $\geq$ 40) and PTSD (PPQ $\geq$ 19)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Turkey	Cross-		223	2 days	
	Ostacoli, 2020	Italian			163	4 months	Depression (EPDS $\geq$ 11) and PTSD (IES- $R \geq$ 24)
	Spinola, 2020	Italian			243	1 year	Depression (EPDS $\geq$ 13) and Anxie (PSS $\geq$ 28)
	Stojanov, 2020	Serbia			108	1 year	Depression (EPDS $\geq$ 10)
	Sun, 2020	China			2092	1 week	Depression (EPDS $\geq 10$ )
sectional (during COVID-19) sectional (during COVID-19) fallon, 2021 lando, 2021 lando, 2021 lando, 2021 lando, 2021 lando, 2021 lando, 2021 lando, 2021 lando, 2020 lando, 202	Zeng, 2020				109	1 week	Depression (EPDS $\geq$ 13) and Anxie (GAD7 $\geq$ 5)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			sectional	(during COVID-19)			-
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	,		sectional	(during COVID-19)			(IES6 $\geq$ 1.75)
2021sectional Chran-Dytkok, 2021PolandCGR- Case- (during COVID-19) 2019/10/1 to 2019/11/10CTA 2-40 and Stress (PSSL0 2 1 Depression (EPDS $\geq 12$ )2021Control(during COVID-19) 2019/10/1 to 2019/11/10781 yearDepression (EPDS $\geq 12$ )1amani, 2020IsraelCase- (during COVID-19) 2016/10/1 to 2017/4/1793 daysDepression (EPDS $\geq 10$ )1amani, 2020SraelCase- (during COVID-19) (during COVID-19) (during COVID-19)751 dayDepression (EPDS $\geq 10$ )1ut, 2020ChinaCase- (during COVID-19) (during COVID-19)3577 (during COVID-19)11ut, 2020SpainCase- (during COVID-19) (during COVID-19)1 monthDepression (EPDS $\geq 10$ )1ut, 2020IsraelCase- (during COVID-19) (during COVID-19)1 monthDepression (EPDS $\geq 10$ )2016/1/1 to 2017/4/3577 (during COVID-19) (during COVID-19)1 monthDepression (EPDS $\geq 10$ )2016/1/1 to 2017/4/3577 (during COVID-19)1 monthDepression (EPDS $\geq 10$ )2016/1/1 to 2017/4/1123 (during COVID-19)2212 daysDepression (EPDS $\geq 10$ )2016/1/1 to 2017/4/1123 (during COVID-19)2212 daysDepression (EPDS $\geq 9$ )2016/1/1 to 2020/3/1 to 2020/3/3 to 2020/3/2052N.A.Depression (EPDS $\geq 9$ )2016/1/1 to 2020/3/1 to 2020/3/3 to 2020/3/31 monthDepression (EPDS $\geq 13$ )2016/1/1 to 2020/3/1 to 2020/3/3 to 2020/3/31 monthDepression (EPDS $\geq 13$ ) <t< td=""><td></td><td>0</td><td>sectional</td><td>(during COVID-19)</td><td></td><td>-</td><td>(STAI ≥40)</td></t<>		0	sectional	(during COVID-19)		-	(STAI ≥40)
2021         control (during COVID-19)         (during COVID-19)         64           4anami, 2020         Israel         Case:         2020/5/1 to 2020/5/1 0         79         3 days         Depression (EPDS ≥10)           4anami, 2020         Israel         Case:         2020/5/1 to 2020/5/1 0         79         3 days         Depression (EPDS ≥10)           4ut, 2020         China         Case:         2020/1/5 to 2020/1/4         75         1 day         Depression (EPDS ≥10)           4ut, 2020         China         Case:         2020/1/5 to 2020/1/4         357         1 month         Depression (EPDS ≥10)           4utrino:         Spain         Case:         2020/1/1 to 2020/1/1         75         1 month         Depression (EPDS ≥10)           Narvace, 2021         Case:         2020/1/1 to 2020/1/1         75         1 month         Depression (EPDS ≥10)           Narvace, 2021         Case:         2020/3/1 to 2020/1/1         75         1 month         Depression (EPDS ≥10)           Mariño:         Spain         Case:         2020/3/1 to 2020/4/20         2         2         2 days         Depression (EPDS ≥10)           Silverman, 2020         Mara         Case:         2020/3/1 to 2020/4/21         2         2         2         2	2021		sectional	COVID-19)			(STAI $\geq$ 40) and Stress (PSS10 $\geq$ 1
Hamani, 2020     Israel     Case- control     2020/5/1 to 2020/5/31     79     3 days     Depression (EPDS ≥10)       Hui, 2020     China     Case- control     2016/10/1 to 2017/4/1     123       Hui, 2020     China     Case- control     2020/5/1 to 2020/7/1     954     1 day     Depression (EPDS ≥10)       Mariño- Narvaez, 2021     Spain     Case- control     2019/1/5 to 2020/1/1     357     1     Depression (EPDS ≥10)       Mariño- Narvaez, 2021     Spain     Case- control     2019/1/5 to 2020/1/1     357     1     Depression (EPDS ≥10)       Narvaez, 2020     Spain     Case- control     2019/1/5 to 2020/1/1     357     1     Depression (EPDS ≥10)       Pariente, 2020     Israel     Case- control     2016/1/1 to 2020/1/1     82     2     days     Depression (EPDS ≥10)       Pariente, 2020     Israel     Case- control     2020/2/1 to 2020/2/12     23     2 days     Depression (EPDS ≥10)       Pariente, 2020     Israel     Case- control     2020/2/1 to 2017/4/12     12     2       Superssion (EPDS ≥10)     Case- control     2020/2/1 to 2020/3/13     14     1 month     Depression (EPDS ≥9)       Superssion (EPDS ≥10)     Case- control     2020/2/1 to 2020/3/11     12     2     2     2     2     2	• •	Poland		(during COVID-19) 2019/10/1 to 201,911/10		1 year	Depression (EPDS $\geq$ 12)
$ \begin{tabular}{ c c c c } &  c c c c c c c c c c c c c c c c c c $	Hamami, 2020	Israel		2020/5/1 to 2020/5/31	79	3 days	Depression (EPDS $\geq$ 10)
Hui, 2020         Kina         Case- orano         2020/1/5 to 2020/1/3         954         I day         Depression (EPDS ≥10)           Aurino- Narvez, 2021         Spain         Case- orano         2020/4/1 to 2020/1/1         3577         I month         Depression (EPDS ≥10)           Narvez, 2021         Spain         Case- orano         2020/4/1 to 2020/7/1         75         I month         Depression (EPDS ≥10)           Pariente, 2020         Israel         Case- orano         2020/4/1 to 2020/7/1         72         I month         Depression (EPDS ≥10)           Pariente, 2020         Israel         Case- orano         2020/4/1 to 2020/7/1         72         2 days         Depression (EPDS ≥10)           Pariente, 2020         Israel         Case- orano         2020/3/1 to 2020/4/29         23         2 days         Depression (EPDS ≥10)           Pariente, 2020         Israel         Case- orano         2020/3/1 to 2020/4/19         123         Pariente, 2020         Pariente, 2020/3/1 to 2020/2/12         Pariente, 2020/3/10				2016/10/1 to 2017/4/1	123		
$ \begin{tabular}{ c                                   $	Hui, 2020	China			954	1 day	Depression (EPDS $\geq$ 10)
Narvaez, 2021 control (during COVID-19) 2019/9/1 to 2020/3/1 & 82 (before COVID-19) 2016/9/1 to 2020/3/18 to 2020/4/29 223 2 days Depression (EPDS $\geq 10$ ) (during COVID-19) 2016/11 to 2017/4/1 123 (before COVID-19) 2016/11 to 2017/4/1 123 (before COVID-19) 2020/2/1 to 2020/3/12 to 2020/3/2 264 (before COVID-19) 2020/2/1 to 2020/3/13 148 1 month Depression (EPDS $\geq 9$ ) control (during COVID-19) 2020/2/1 to 2020/3/13 to 2020/4/13 148 1 month Depression (EPDS $\geq 9$ ) control (during COVID-19) 2019/3/1 to 2020/4/13 148 1 month Depression (EPDS $\geq 9$ ) control (during COVID-19) 2019/3/8 to 2019/4/11 132 (before COVID-19) 2019/3/8 to 2019/3/1 to 2020/5/3 91 2 days Depression (EPDS $\geq 13$ ) control (during COVID-19) 2019/3/8 to 2019/5/3 101 (before COVID-19) 30ekhorst, 2021 Netherlands Case- 2020/3/1 to 2020/5/1 59 8-10 weeks Depression (EPDS $\geq 12$ ) control (during COVID-19) 2019/1/ to 2020/5/1 250 (before COVID-19) 30ekhorst, 2021 Apan Case- 2020/3/1 to 2020/5/1 250 (before COVID-19) 30ekhorst, 2021 Apan Case- 2020/3/1 to 2020/5/1 250 (before COVID-19) 2019/1/7 to 2020/3/1 250 (before COVID-19) 2019/1/7 to 2020/3/1 250 (before COVID-19) 2019/3/1 to 2020/5/1 250 (before COVID-19) 2019/1/1 to 2020/3/1 250 (before COVID-19) 2019/					3577		
Pariente, 2020 Israel Case- 2020/3/18 to 2020/4/29 223 2 days Depression (EPDS ≥10) (during COVID-19) 2016/1/1 to 2017/4/1 123 (before COVID-19) 2016/1/1 to 2017/4/1 123 (before COVID-19) 2020/3/13 to 2020/6/30 252 N.A. Depression (EPDS ≥9) (during COVID-19) 2020/3/13 to 2020/3/12 0 2020/3/12 2020/3/12 to 2020/3/12 0 2020/3/12 2020/3/12 to 2020/3/12 0 2020/3/12 2020/3/14 to 2020/4/13 148 1 month Depression (EPDS ≥9) (during COVID-19) 2019/3/9 to 2019/4/11 132 (before COVID-19) 2019/3/9 to 2019/4/11 132 (during COVID-19) 2019/3/8 to 2020/5/3 91 2 days Depression (EPDS ≥9) 2019/3/8 to 2020/5/3 91 2 days Depression (EPDS ≥13) (during COVID-19) 2019/3/8 to 2020/5/3 101 (during COVID-19) 2019/3/8 to 2020/5/1 59 2019/3/8 to 2020/5/1 59 2019/2/8 to 2020/5/1 59 2019/1/7 to 2020/3/1 to 2020/6/1 59 2019/1/7 to 2020/3/1 50 2020/3/1 to 2020/6/1 59 2020/2/1 59 2020/2/1 50 2020/2/1		Spain	Case-	2020/4/1 to 2020/7/1	75	1 month	Depression (EPDS $\geq 10$ )
aranente, 2020         Israel         Case- control         2020/3/18 to 2020/4/29         23         2 days         Depression (EPDS ≥10)           1000000000000000000000000000000000000	Narvaez, 2021		control	2019/9/1 to 2020/3/1	82		
ilverman, 2020 US Case- uzuki, 2020 Japan Case- tanardo, 2020 Italy Case- tanardo, 2020 Italy Case- tanardo, 2020 Italy Case- Control Case- Control Case- Case- Control Case- Case- Control Case- Control Case- Case- Control Case- Case- Control Case- Case- Control Case- Case- Control Case- Case- Control Case- Ca	ariente, 2020	Israel		2020/3/18 to 2020/4/29	223	2 days	Depression (EPDS $\geq$ 10)
Silverman, 2020 US Case- control (during COVID-19) 2020/2/1 to 2020/3/12 264 (before COVID-19) 2020/2/1 to 2020/4/13 148 1 month Depression (EPDS ≥9) (before COVID-19) 2019/3/9 to 2019/4/11 132 (before COVID-19) 2019/3/9 to 2019/4/11 132 (before COVID-19) 2019/3/8 to 2019/5/3 91 2 days Depression (EPDS ≥13) (before COVID-19) 2019/3/8 to 2019/5/3 101 (before COVID-19) 2019/3/8 to 2019/5/3 101 (before COVID-19) 2019/1/3 to 2019/5/3 101 (before COVID-19) 2019/1/7 to 2020/5/14 59 8-10 weeks Depression (EPDS ≥12) (before COVID-19) 2019/1/7 to 2020/5/14 59 8-10 weeks Depression (EPDS ≥12) (before COVID-19) 2019/1/7 to 2020/5/14 50 4-10 weeks Depression (EPDS ≥12) (before COVID-19) 2019/1/7 to 2020/3/1 to 2020/5/14 59 8-10 weeks Depression (EPDS ≥12) (before COVID-19) 2019/1/7 to 2020/3/1 to 2020/5/14 50 4-5 weeks Depression (EPDS ≥9) (before COVID-19) 2019/1/7 to 2020/3/1 to 2020/5/14 279 4-5 weeks Depression (EPDS ≥9)			control	2016/11/1 to 2017/4/1	123		
auzuki, 2020 Japan Case- control (during COVID-19) 2019/3/9 to 2019/4/13 148 1 month Depression (EPDS ≥9) (during COVID-19) 2019/3/9 to 2019/4/11 132 (before COVID-19) 2019/3/8 to 2020/5/3 91 2 days Depression (EPDS ≥13) control (during COVID-19) 2019/3/8 to 2020/5/3 101 (before COVID-19) 2019/3/8 to 2019/5/3 101 (before COVID-19) 2019/3/8 to 2019/5/3 101 (before COVID-19) 2019/1/ to 2020/5/14 59 8–10 weeks Depression (EPDS ≥12) control (during COVID-19) 2019/1/ to 2020/5/14 59 8–10 weeks Depression (EPDS ≥12) control (during COVID-19) 2019/1/ to 2020/5/14 59 8–10 weeks Depression (EPDS ≥12) control (during COVID-19) 2019/1/ to 2020/3/1 0 2020/5/14 59 8–10 weeks Depression (EPDS ≥12) control (during COVID-19) 2019/1/ to 2020/3/1 0 2020/5/14 250 (before COVID-19)	ilverman, 2020	US		2020/3/13 to 2020/6/30	252	N.A.	Depression (EPDS $\geq$ 9)
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$				2020/2/1 to 2020/3/12	264		
Kanardo, 2020ItalyCase- Case- control (during COVID-19) 2019/3/8 to 2019/5/391 2 days2 days Depression (EPDS ≥13)Boekhorst, 2021NetherlandsCase- Case- Control2020/3/1 to 2020/5/1459 2019/2/3/1 to 2020/5/1459 2019/2/3/1 to 2020/2/1459 2019/2/3/1 to 2020/2/14Boekhorst, 2021JapanCase- Case- Case- Control2020/3/1 to 2020/6/1279 2794–5 weeks 2019/2/201Depression (EPDS ≥9) 2019/1/1 to 2020/6/1	Suzuki, 2020	Japan			148	1 month	Depression (EPDS $\geq$ 9)
control       (during COVID-19)         2019/3/8 to 2019/5/3       101         (before COVID-19)       101         Boekhorst, 2021       Netherlands       Case-       2020/3/1 to 2020/5/14       59       8–10 weeks       Depression (EPDS ≥12)         Boekhorst, 2021       Netherlands       Case-       2020/3/1 to 2020/5/14       59       8–10 weeks       Depression (EPDS ≥12)         diiragi, 2021       Japan       Case-       2020/3/1 to 2020/6/1       279       4–5 weeks       Depression (EPDS ≥9)         control       (during COVID-19)       control       (during COVID-19)				(before COVID-19)			
beekhorst, 2021 Netherlands Case- tirragi, 2021 Japan Case- Case- tirragi, 2021 Japan Case- Cas	Zanardo, 2020	Italy		(during COVID-19)		2 days	Depression (EPDS $\geq$ 13)
iiiragi, 2021 Japan Case- 2020/3/1 to 2020/6/1 279 4–5 weeks Depression (EPDS ≥9) control (during COVID-19)	11	N 4 1 1	0	(before COVID-19)		0.10	
(before COVID-19)           diiragi, 2021         Japan         Case-         2020/3/1 to 2020/6/1         279         4–5 weeks         Depression (EPDS ≥9)           control         (during COVID-19)	30ekhorst, 2021	Netherlands		(during COVID-19)		8–10 weeks	Depression (EPDS $\geq$ 12)
control (during COVID-19)	Jiimai 2021	Ionon	Cons	(before COVID-19)		4 E	Depression (EDDC $\geq 0$ )
	1117agi, 2021	Japali				4–5 weeks	Depression (EPDS ≥9)

(continued on next page)

#### Table 1 (continued)

First author and Year	Country	Study design	Study periods	Sample size	Time after delivery	Outcomes and assessment scales
Lorentz, 2021	Brazil	Panel study	2019/3/1 to 2019/6/1 (before COVID-19) 2020/5/1 to 2020/9/1	50	6 months	Depression (EPDS >10)
lorente, 2021	Dideli	T uncr study	(during COVID-19) 2019/11/1 to 2020/3/1 (before COVID-19)		0 day	
Loret de Mola, 2021	Brazil	Panel study	2020/5/11 to 2020/7/20 (during COVID-19) 2019/1/1 to 2019/12/31 (before COVID-19)	1136	>4.5 months	Depression (EPDS ${\geq}13$ ), Anxiety (GAD7 ${\geq}$ 10) and Stress (IES ${\geq}$ 26)
Racine, 2021	Canada	Panel study	2020/5/20 to 2020/7/15 (during COVID-19)	1333	>9 years	Depression (CES-D-10 $\geq$ 10) and Anxiety (STAI-SF $\geq$ 14)
			2017/2/1 to 2019/10/1 (before COVID-19)	2074		

COVID-19, coronavirus disease 2019; PTSD, post-traumatic stress disorder; PHQ9, the 9-item Patient Health Questionnaire; EPDS, the Edinburgh Postnatal Depression scale; GAD7, the 7-item Generalized Anxiety Disorder scale; STAI, the State Trait Anxiety Inventory scale; PPQ, the Perinatal PTSD Questionnaire; IES-R, the Impact of Event Scale-Revised; PSS, the Perceived Stress Scale; PHQ4, the Patient Health Questionnaire-4; IES6, the Impact of Event Scale-6; PSS10, the 10-item Perceived Stress Scale; IES, the Impact of Event scale; CES-D-10, the 10-item Center for Epidemiological Studies Depression scale; STAI-SF, the 6-item short form of the Spielberger State-Trait Anxiety Inventory.

as a medium-quality, whereas <3 as a low-quality (Sun et al., 2020a). The quality of included panel studies was assessed by Newcastle-Ottawa-Scale (NOS) including 8 items (Wells et al., n.d.). We considered a panel study scored  $\geq$ 7 as a high-quality study.

#### 2.5. Statistical analysis

Quantitative meta-analysis was conducted for psychological health symptoms, which have relevant data reported in more than one study. The pooled prevalence with its 95 % confidence interval (CI) for each adverse psychological symptom during the COVID-19 pandemic was estimated using logit-transformed prevalence rate and its standard error (SE) in each study and presented as forest plots. Subgroup analyses were performed based on several study-level characteristics including continent, study design, assessment scale, time after delivery, survey method and study quality. The association between risk factors and postpartum psychological symptoms during the COVID-19 pandemic was summarized using study-specific odds ratio (OR) with its 95 % CI. The effects of COVID-19 pandemic on the postpartum depressive or anxiety symptoms were evaluated by the pooled OR with its 95%CI from studies provided data both before and during the COVID-19 pandemic. Subgroup analyses were also performed. The DerSimonian and Laird random effects model was selected for meta-analysis when statistical heterogeneity was detected using the *p*-value <0.05 in Cochran Q test or the I<sup>2</sup> statistics >50 % (DerSimonian and Laird, 1986; Higgins et al., 2003). Otherwise, an inverse variance fixed effect model was adopted (Blettner et al., 1999). Publication bias was assessed using funnel plots and Egger's test if enough original studies (n > 10) were available. R software (version 4.1.0) was used to perform all data analyses.

#### 3. Results

#### 3.1. Literature search

Fig. 1 presents a flowchart of the study selection process. Overall, 679 relevant references were identified in the literature search, and 634 studies were excluded through screening of titles and abstracts. This left 45 papers for full-text screening, of which 16 were excluded: data for postpartum women were not reported separately in nine studies (Li et al., 2021; Masters et al., 2021; Perzow et al., 2021; Wang et al., 2021; Liu et al., 2021; Stepowicz et al., 2020; Xue et al., 2021; Chaves et al., 2022; Farewell et al., 2020; psychological health symptoms were not screened by validated scales in three studies (Dib et al., 2020; Ollivier et al., 2021; Jafree et al., 2021), and four studies reported the mean

score for psychological health symptoms instead of prevalence (Mayopoulos et al., 2021; McFarland et al., 2021; Shayganfard et al., 2020; Fernandes et al., 2021). Finally, 29 articles were included in the metaanalysis (Loret de Mola et al., 2021; Pariente et al., 2020; Racine et al., 2021; Silverman et al., 2020; An et al., 2021; Basu et al., 2021; Bo et al., 2020; Boekhorst et al., 2021; Ceulemans et al., 2020; Chrzan-Dętkoś et al., 2021; Fallon et al., 2021; Guvenc et al., 2021; Hamami et al., 2020; Hiiragi et al., 2021; Hui et al., 2021; Liang et al., 2020; Lorentz et al., 2020; Mariño-Narvaez et al., 2021; Molgora and Accordini, 2020; Oskovi-Kaplan et al., 2021; Suárez-Rico et al., 2020; Spinola et al., 2020; Stojanov et al., 2021; Suárez-Rico et al., 2020).

#### 3.2. Study characteristics

Details of the 29 included studies are shown in Table 1. These 29 studies involved 20,225 postpartum women during the COVID-19 pandemic and 8312 postpartum women before the COVID-19 pandemic. There were two multinational studies that recruited participants from five and 64 countries, respectively (Basu et al., 2021; Ceulemans et al., 2021). The remaining 27 studies were conducted in 16 different countries over four continents (Loret de Mola et al., 2021; Pariente et al., 2020; Racine et al., 2021; Silverman et al., 2020; An et al., 2021; Bo et al., 2020; Boekhorst et al., 2021; Ceulemans et al., 2020; Chrzan-Dętkoś et al., 2021; Fallon et al., 2021; Guvenc et al., 2021; Hamami et al., 2020; Hiiragi et al., 2021; Hui et al., 2021; Liang et al., 2020; Lorentz et al., 2020; Mariño-Narvaez et al., 2021; Molgora and Accordini, 2020; Oskovi-Kaplan et al., 2021; Ostacoli et al., 2020; Spinola et al., 2020; Stojanov et al., 2021; Suárez-Rico et al., 2021; Sun et al., 2020b; Suzuki, 2022; Zanardo et al., 2020; Zeng et al., 2020). There were 16 cross-sectional studies that reported prevalence rates of psychological health symptoms during the COVID-19 pandemic (An et al., 2021; Basu et al., 2021; Bo et al., 2020; Ceulemans et al., 2021; Ceulemans et al., 2020; Fallon et al., 2021; Guvenc et al., 2021; Liang et al., 2020; Molgora and Accordini, 2020; Oskovi-Kaplan et al., 2021; Ostacoli et al., 2020; Spinola et al., 2020; Stojanov et al., 2021; Suárez-Rico et al., 2021; Sun et al., 2020b; Zeng et al., 2020). The remaining 10 case-control studies (Pariente et al., 2020; Silverman et al., 2020; Boekhorst et al., 2021; Chrzan-Dętkoś et al., 2021; Hamami et al., 2020; Hiiragi et al., 2021; Hui et al., 2021; Mariño-Narvaez et al., 2021; Suzuki, 2022; Zanardo et al., 2020) and three panel studies (Loret de Mola et al., 2021; Racine et al., 2021; Lorentz et al., 2020) compared the differences in the risk for psychological health symptoms before and during the COVID-19 pandemic. The total sample size ranged from 50 to

#### Table 2

The methodological quality of the included studies.

Author, year	Source of information	Inclusion/ exclusion criteria	Time period for identity	Subjects consecutive	Evaluators masked	Quality assurance assessments	Patient exclusions	Confounding assessed/ controlled	Missing data	Response rates	Follow- up	Total
Cross-sectiona	l and case-contr	ol studies										
Bo, 2021	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	No	6
Ceulemans, 2021	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	No	7
Ceulemans, 2020	Yes	No	No	No	No	Yes	No	No	No	No	No	2
Guvenc, 2020	Yes	Yes	Yes	No	No	Yes	Yes	No	No	Yes	No	6
Liang, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	9
Molgora, 2020	Yes	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	7
Oskovi- Kaplan, 2020	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes	No	7
Ostacoli, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	9
Spinola, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	No	No	6
Stojanov, 2020	Yes	Yes	Yes	No	No	Yes	Yes	No	No	No	No	5
Sun, 2020	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No	No	No	6
Zeng, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	No	Yes	No	8
An, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	9
Basu, 2020	Yes	Yes	Yes	No	No	Yes	Unclear	Yes	Yes	No	No	6
Fallon, 2021	Yes	Yes	Yes	No	No	Yes	No	Yes	No	Yes	No	6
Suárez- Rico, 2021	Yes	Yes	Yes	No	No	Yes	Yes	No	Yes	Yes	No	7
Chrzan- Dętkoś, 2021	Yes	Yes	Yes	No	No	Yes	No	No	Yes	No	No	5
Hamami, 2020	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	No	Yes	No	7
Hui, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	Yes	8
Mariño- Narvaez, 2021	Yes	Yes	Yes	No	No	Yes	Yes	No	No	No	No	5
Pariente, 2020	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No	No	No	6
Silverman, 2020	Yes	Yes	Yes	Yes	No	Yes	No	No	No	No	No	5
Suzuki, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No	Yes	No	7
Zanardo, 2020	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	9
Boekhorst, 2021	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	Yes	No	8
Hiiragi, 2021	Yes	Yes	Yes	Unclear	No	Yes	Yes	Yes	Yes	Yes	No	8

Author, Year	Representativeness of the exposed cohort	Selection of unexposed cohort	Assessment of exposure	Absence of outcome at start of study	Comparability	Outcome assessment	Follow-up period	Adequacy of follow-up	Total
Panel studies									
Lorentz, 2021	-	1	1	1	2	-	1	1	7
Loret de Mola, 2021	-	1	1	1	2	-	1	1	7
Racine, 2021	1	1	1	1	2	_	1	1	8

5134 postpartum women from 0 days to >9 years after delivery. All 29 studies reported rates of postpartum depressive symptoms, with the Edinburgh Postnatal Depression scale (EPDS) (cut-off points from 9 to 13) used in 25 studies (Loret de Mola et al., 2021; Pariente et al., 2020; Silverman et al., 2020; An et al., 2021; Boekhorst et al., 2021; Ceulemans

et al., 2021; Ceulemans et al., 2020; Chrzan-Dętkoś et al., 2021; Fallon et al., 2021; Guvenc et al., 2021; Hamami et al., 2020; Hiiragi et al., 2021; Hui et al., 2021; Liang et al., 2020; Lorentz et al., 2020; Mariño-Narvaez et al., 2021; Molgora and Accordini, 2020; Oskovi-Kaplan et al., 2021; Ostacoli et al., 2020; Spinola et al., 2020; Stojanov et al., 2021;



Fig. 2. The pooled prevalence of postpartum psychological symptoms during the COVID-19 pandemic. (A) postpartum depressive symptoms. (B) postpartum anxiety symptoms. (C) postpartum stress symptoms. (D) postpartum post-traumatic stress disorder symptoms.

Suárez-Rico et al., 2021: Sun et al., 2020b: Suzuki, 2022; Zanardo et al., 2020; Zeng et al., 2020). The other three studies used the 9-item Patient Health Questionnaire (PHQ9), the Patient Health Questionnaire-4 (PHQ4), and the 10-item Center for Epidemiological Studies Depression scale (CES-D-10) with cut-off points of 5,6, and 10, respectively (Racine et al., 2021; Basu et al., 2021; Bo et al., 2020). Nine studies reported the prevalence of postpartum anxiety using the 7-item Generalized Anxiety Disorder scale (GAD7), the Perceived Stress Scale (PSS), the State Trait Anxiety Inventory scale (STAI), or the 6-item short form of the Spielberger State-Trait Anxiety Inventory (STAI-SF) (Loret de Mola et al., 2021; Racine et al., 2021; Ceulemans et al., 2021; Ceulemans et al., 2020; Fallon et al., 2021; Molgora and Accordini, 2020; Spinola et al., 2020; Suárez-Rico et al., 2021; Zeng et al., 2020). In addition, the prevalence of postpartum stress and post-traumatic stress disorder (PTSD) symptoms were reported by two (Loret de Mola et al., 2021; Suárez-Rico et al., 2021) and three studies (Basu et al., 2021; Molgora and Accordini, 2020; Ostacoli et al., 2020), respectively. The methodological quality scores for the included studies are shown in Table 2, and 11 were high-quality studies (Loret de Mola et al., 2021; Racine et al., 2021; An et al., 2021; Boekhorst et al., 2021; Hiiragi et al., 2021; Hui et al., 2021; Liang et al., 2020; Lorentz et al., 2020; Ostacoli et al., 2020; Zanardo et al., 2020; Zeng et al., 2020).

#### 3.3. Postpartum psychological health during the COVID-19 pandemic

#### 3.3.1. Postpartum depressive symptoms

The rate of postpartum depressive symptoms during the COVID-19 pandemic was evaluated in 29 studies and ranged from 8.5 % to 74.4 %. The pooled prevalence of postpartum depressive symptoms was 26.7 % (95 % CI: 22.0 %-31.9 %), as shown in Fig. 2A. Results from subgroup analyses are shown in Fig. 3. Ten studies were performed in Asia and the pooled prevalence of depressive symptoms in these studies was 23.2 % (95%CI: 17.1 %-30.7 %). Thirteen studies provided data from Europe with a pooled prevalence of depressive symptoms of 28.0 % (95%CI: 19.7 %–38.1 %). The three studies conducted in North America and two studies conducted in South America reported pooled prevalence rates of 27.3 % (95%CI: 16.5 %-41.8 %) and 32.7 % (95%CI: 24.1 %-42.6 %), respectively (Fig. 3A). The pooled prevalence rates of depressive symptoms in cross-sectional, case-control, and panel studies were 28.0 % (95%CI: 21.4 %-35.7 %), 22.3 % (95%CI: 14.8 %-32.1 %), and 33.2 % (95%CI: 28.3 %-38.6 %), respectively (Fig. 3B). Twenty-six studies used the EPDS to assess postpartum depression, and the pooled prevalence was 26.1 % (95%CI: 21.0 %-32.0 %). The studies that used the CES-D-10, PHQ4, and PHQ9 reported postpartum depression rates of 35.2 % (95%CI: 32.7 %-37.8 %), 30.7 % (95%CI: 28.1 %-33.4 %), and 27.6 % (95%CI: 23.4 %-31.9 %), respectively (Fig. 3C). The prevalence of postpartum depressive symptoms in studies that used an online survey was 32.3 % (95%CI: 26.0 %-39.2 %), which was higher than the prevalence in non-online survey studies (16.3 %, 95%CI: 13.4 %-19.7 %) (Fig. 3D). Data for time after delivery were available for 26 studies. The pooled prevalence rate of depressive symptoms in women whose postpartum duration was <6 weeks was 21.7 % (95%CI: 16.5 %-28.1 %) and that in women >6 weeks after delivery was 32.3 % (95%CI: 24.8 %-40.8 %) (Fig. 3E). Among the 11 high-quality studies, the pooled postpartum depressive symptom rate was 26.7 % (95%CI: 20.4 %-34.1 %), which was similar to that among moderate-quality studies (27.9%, 95% CI: 21.6 %-35.4 %). Only one low-quality study reported the prevalence rate of postpartum depression (13.0 %, 95%CI: 11.9 %-14.2 %) (Fig. 3F). Summary risk estimates of associations between risk factors and postpartum depression during the COVID-19 pandemic are shown in Table 3. Both lower income (OR = 1.28, 95%CI: 1.06-1.54) and formula feeding (OR = 1.58, 95%CI: 1.21–2.07) significantly increased the risk for postpartum depression. Similar but borderline significant associations were found for maternal age < 35 years (OR = 1.18, 95%CI: 0.93–1.50) and an education below a high school degree (OR = 1.13, 95%CI: 0.92–1.39). Employment, first pregnancy (OR = 1.22, 95%CI: 0.74-2.01), and cesarean delivery (OR = 0.96, 95%CI: 0.76-1.21) did not show any association with postpartum depression.

#### 3.3.2. Postpartum anxiety symptoms

The prevalence of postpartum anxiety symptoms was reported in nine studies. As shown in Fig. 2B, the pooled rate of anxiety symptoms was 33.8 % (95%CI: 21.1 %-49.4 %). Subgroup analyses are shown in Fig. 4. Pooled analyses by continent revealed that the prevalence of postpartum anxiety symptoms was similar in Europe (34.3 %, 95%CI: 15.1 %-60.5 %) and North America (38.3 %, 95%CI: 25.2 %-53.3 %). Only one study was conducted in Asia and one in South America, and these studies reported lower postpartum anxiety rates (31.2 %, 95%CI: 23.2 %-40.5 % and 25.9 %, 95%CI: 23.4 %-28.5 %, respectively) (Fig. 4A). The pooled prevalence rate of anxiety symptoms was 35.5 % (95%CI: 18.4 %-57.3 %) in cross-sectional studies, which was higher than that in panel studies (28.6 %, 95%CI: 23.5 %-34.4 %) (Fig. 4B). The prevalence of anxiety symptoms assessed by the STAI (55.0 %, 95%CI: 45.4 %-64.3 %) and PSS (51.9 %, 95%CI: 45.4 %-58.3 %) was higher than that assessed by the GAD7 (18.3 %, 95%CI: 11.4 %-28.2 %) and STAI-SF (31.4 %, 95%CI: 29.0 %-34.0 %) (Fig. 4C). Most studies adopted an online survey method, which yielded a pooled prevalence for anxiety symptoms of 34.2 % (95%CI: 20.6 %-50.9 %). Only one study



**Fig. 3.** Subgroup analysis of the prevalence of postpartum depressive symptoms during the COVID-19 pandemic by (A) continent, (B) study design, (C) assessment scale, (D) time after delivery, (E) survey method, (F) study quality. Abbreviations: CES-D-10, the 10-item Center for Epidemiological Studies Depression scale; EPDS, the Edinburgh Postnatal Depression scale; PHQ4, the Patient Health Questionnaire-4; PHQ9, the 9-item Patient Health Questionnaire.

#### Table 3

Summary risk estimates of association between risk factors and postpartum depression during the COVID-19 pandemic.

Risk factors	Studies, N	Summary OR (95%	Hetero	Heterogeneity		
		CI)	I <sup>2</sup> , %	p-value		
Maternal age < 35 years	3	1.18 (0.93–1.50)	0	0.504		
Employment	4	1.20 (0.71-2.02)	81.9	< 0.05		
Under high school degree	5	1.13 (0.92–1.39)	0	0.779		
Lower income level	4	1.28 (1.06-1.54)	0	0.811		
First pregnancy	2	1.22 (0.74-2.01)	56.1	0.131		
Cesarean section	4	0.96 (0.76-1.21)	0	0.763		
Formula feeding	2	1.58 (1.21–2.07)	41.8	0.190		

N, number; OR, odds ratio; CI, confidence interval.

did not use online survey and reported a prevalence of anxiety symptoms of 31.2 % (95%CI: 23.2 %–40.5 %) (Fig. 3D). Seven studies included women >6 weeks after delivery. The pooled prevalence for anxiety symptoms of these seven studies was 38.0 % (95%CI: 21.4 %–58.0 %), which was higher than that in women <6 weeks after delivery reported in one study (31.2 %, 95%CI: 23.2 %–40.5 %) (Fig. 3E). Among the three high-quality studies, the pooled rate of anxiety symptoms was 29.1 % (95%CI: 24.8 %–33.8 %), which was lower than that among the five moderate-quality studies (42.2 %, 95%CI: 15.6 %–74.3 %) (Fig. 3F). Risk factor analyses were not performed because of the limited number of original studies.

#### 3.3.3. Prevalence of postpartum stress and PTSD

The pooled prevalence of postpartum stress was 55.0 % (95%CI: 27.9 %–79.5 %) and that of PTSD was 33.7 % (95%CI: 19.6 %–51.5 %), as reported in two and three studies, respectively (Fig. 2C and D). Subgroup and risk factor analyses were not performed for stress and PTSD in postpartum women because of the limited number of original studies.

## 3.4. Effects of COVID-19 pandemic on postpartum depressive and anxiety symptoms

#### 3.4.1. postpartum depressive symptom

Thirteen studies reported the difference in postpartum depression prevalence rates before and during the COVID-19 pandemic. As shown in Fig. 5A, the pooled OR for postpartum depression during the COVID-19 pandemic was 1.54 (95 % CI: 1.00-2.36). Subgroup analyses are shown in Fig. 6. Pooled analyses by continents revealed that the risk for postpartum depression during the COVID-19 pandemic was significantly increased in Europe (OR = 1.95, 95%CI: 1.32-2.87) and South America (OR = 4.32, 95% CI: 1.21-15.41) compared with Asia (OR = 0.94, 95%)CI: 0.63-1.41) and North America (OR = 1.41, 95%CI: 0.50-3.94) (Fig. 6A). The pooled OR during the COVID-19 pandemic in case-control studies was 1.15 (95 % CI: 0.85-1.56), which was lower than that in panel studies (OR = 3.47, 95 % CI: 1.34-8.95) (Fig. 6B). Nearly all studies (12 of 13) adopted the EPDS to assess postpartum depression, and the pooled OR during COVID-19 pandemic in these 12 studies was 1.47 (95%CI: 0.86-2.53). Only one study used the CES-D-10 to identify postpartum depressive symptoms, and that study reported a higher OR during the COVID-19 pandemic (OR = 2.31, 95%CI: 1.98-2.71) (Fig. 6C). The pooled OR during the COVID-19 pandemic was 1.40 (95 % CI: 0.77-2.55) in the two studies that used online surveys in both the pre- and post-pandemic periods, which was higher than the OR in the other seven non-online survey studies (OR = 1.04, 95%CI: 0.73-1.50). Four studies used offline and online surveys before and during COVID-19, respectively, which yielded the highest pooled OR during the pandemic (OR = 3.10, 95%CI: 1.42-6.78) (Fig. 6D). Compared with women  $\leq 6$  weeks after delivery (OR = 1.18, 95%CI: 0.80–1.75), the pooled OR for depressive symptom during the COVID-19 pandemic was higher in those >6 weeks after delivery (OR = 2.49, 95%CI: 1.20–5.17)

(Fig. 6E). Among the seven high-quality studies, the risk for postpartum depression during the COVID-19 pandemic was significantly increased (OR = 2.26, 95 % CI: 1.30-3.91), but this association was not found in the six moderate-quality studies (OR = 0.95, 95%CI: 0.62-1.48) (Fig. 6F).

#### 3.4.2. Postpartum anxiety symptoms

Only two studies reported the difference in postpartum anxiety symptoms before and during the COVID-19 pandemic, and the pooled OR during the COVID-19 pandemic was 2.56 (95%CI: 1.62–4.04) (Fig. 5B). A subgroup analysis was not conducted because of the limited number of studies.

#### 3.5. Publication bias

The funnel plot and Egger's test revealed there was no significant publication bias in the prevalence of postpartum depressive symptoms (Fig. 7).

#### 4. Discussion

To our knowledge, this systematic review and meta-analysis of 29 studies is the first to identify an association between COVID-19 pandemic and psychological health symptoms in postpartum women. The results of our analyses revealed that a high proportion of postpartum women suffered from psychological symptoms during the COVID-19 pandemic, with this prevalence significantly higher than before the COVID-19 pandemic. Women >6 weeks after delivery, younger than 35 years, with a low income, with less education, and that used formula feeding had a higher risk for psychological disorders after delivery.

In our systematic review and meta-analysis, we found that the prevalence of postpartum depressive, anxiety, stress, and PTSD symptoms during the COVID-19 pandemic was 26.7 %, 33.8 %, 55.0 %, and 33.7 %, respectively, which were similar to ai previous meta-analyses of mental health among perinatal women during the COVID-19 pandemic (Shorey et al., 2021; Yan et al., 2020). In addition, the results of the present study showed that compared with the general population, postpartum women faced a higher risk for psychological disorders during the COVID-19 pandemic (Krishnamoorthy et al., 2020). These findings were consistent with a previous study involving perinatal women (Basu et al., 2021), which suggested that new mothers faced tremendous social, biological, and psychological changes, making them more susceptible to negative emotions than the general population (Kolakowsky-Hayner et al., 2021; Vesga-Lopez et al., 2008).

Several socio-demographic risk factors for postpartum psychological disorders during the COVID-19 pandemic were identified in the present study. First, we found that the prevalence of postpartum depressive and anxiety symptoms was higher in women >6 weeks after delivery, whereas the prevalence was lower in the first 6 weeks of the postpartum period. The results of previous literature on the peak period for postpartum mental disorders are inconsistent. Some studies indicated that the prevalence of postpartum depression was higher during the first 3 months after delivery (Cooper et al., 1988). However, longitudinal research showed that depressive symptoms persisted for >1 year after delivery (Woolhouse et al., 2015). Evidence from a randomized controlled trial also revealed that the risk for postpartum depression increased 6 weeks after delivery and lasted to 3 months after delivery (Sangsawang et al., 2022). It is important to note that new mothers faced a more challenging and complex environment during the COVID-19 pandemic compared with before the pandemic. With increasing time after delivery, more mothers and babies need activities outside the home. The conflict between outdoor needs and quarantine measures may contribute to the increased prevalence of postpartum psychological disorders during the COVID-19 pandemic (Zanardo et al., 2020).

Second, we found a higher risk for postpartum depression in mothers who were younger than 35 years compared with older mothers. Similar

S. Gao et al.



**Fig. 4.** Subgroup analysis of the prevalence of postpartum anxiety symptoms during the COVID-19 pandemic by (A) continent, (B) study design, (C) assessment scale, (D) time after delivery, (E) survey method, (F) study quality. Abbreviations: GAD7, the 7-item Generalized Anxiety Disorder scale; PSS, the Perceived Stress Scale; STAI, the State Trait Anxiety Inventory scale; STAI-SF, the 6-item short form of the Spielberger State-Trait Anxiety Inventory.

results were also found in other studies that showed older postpartum or pregnant women were less likely to experience anxiety and depression regardless of timing (i.e., before or during the COVID-19 pandemic) (Fan et al., 2021; Alshikh Ahmad et al., 2021). A previous study suggested that the median age-of-onset for mental disorders ranged from late teens through the early 20s before the COVID-19 pandemic (Kessler et al., 2007). In addition, the high risk for postpartum psychological disorders in younger mothers may be attributable to the lack of experience in caring new babies and relieving negative emotion.

Third, lower income or education level, rather than unemployment, was significantly associated with a higher prevalence of postpartum depression. The evidence before the COVID-19 pandemic revealed that lower income level was a risk factor for postpartum psychological disorders (Alshikh Ahmad et al., 2021; Zhao and Zhang, 2020). Furthermore, a previous study showed that around half of families experienced joblessness or income disruption during the COVID-19 pandemic (Racine et al., 2021). Therefore, finical pressure from raising newborns may be more severe, resulting in a higher prevalence of postpartum psychological disorders during the COVID-19 pandemic (Li et al., 2020a). Furthermore, people with a lower education level may have less capabilities to obtain, interpret, and update information about the disease than people with a higher education level, which may increase postpartum women's worries about the pandemic, and therefore affect postpartum mental health (Alshikh Ahmad et al., 2021). Interestingly,



Fig. 5. The pooled odds ratio of COVID-19 pandemic on (A) postpartum depressive symptoms, and (B) postpartum anxiety symptoms.

employment did not significantly decrease postpartum depressive symptoms in our meta-analysis. Having to give up growth opportunities such as attending meetings or travelling for work, as well as making special leave arrangements may increase job uncertainty, which could lead to negative emotions among employees during infectious disease outbreaks (Brooks et al., 2020). This may counteract the benefits from employment, such as increases in income or social interactions, and explain the insignificant association between employment and postpartum psychological disorders during the COVID-19 pandemic (Guintivano et al., 2018).

Fourth, mothers that used formula feeding had an increased risk for postpartum depression during the COVID-19 pandemic. This finding was consistent with most previous studies both before and during the COVID-19 pandemic (Ceulemans et al., 2021; Haga et al., 2012). Formula feeding may decrease the protective effects of a satisfactory mother-infant relationship and increase economic pressure, thereby raising the risk for postpartum psychological disorders during the COVID-19 pandemic.

Before the COVID-19 pandemic, nearly 20 % of postpartum women suffered from depression or anxiety (Howard et al., 2014; Dennis et al., 2017), which was significantly lower than the prevalence during the COVID-19 pandemic. Evidence from pregnant women and the general population also revealed that the COVID-19 outbreak significantly increased the risk for negative emotions or psychological symptoms, which was consistent with our finding among postpartum women (Yan et al., 2020; Ayaz et al., 2020; Yuan et al., 2020; Li et al., 2020b). We found that the COVID-19 pandemic significantly increased the risk for postpartum psychological disorders: the pooled ORs during the COVID-19 pandemic for postpartum depressive and anxiety symptoms were 1.54 (95 % CI: 1.00-2.36) and 2.56 (95%CI: 1.62-4.04), respectively, and women with >6 weeks after delivery were more sensitive to the negative effects of the COVID-19 pandemic. Numerous risk factors increased during the COVID-19 pandemic, such as medical inconvenience, fear of being infected by the COVID-19, lack of social support,

financial stress, and prenatal psychological disorders, which may explain its negative effects on postpartum psychological health (Payne and Maguire, 2019).

Subgroup analyses in the present study showed that women from Asian countries had a lower risk for psychological disorders after delivery compared with women from other countries. This was consistent with the results of a previous meta-analysis among pregnant women in which Europe had the highest prevalence of anxiety or depressive symptoms, followed by Asia and North America (Shorey et al., 2021). An international cross-sectional study among perinatal women revealed that after adjusting for various risk factors, the prevalence of anxiety, depression, and PTSD in other regions were 1.5 to 3 times significantly higher than that in Asia during the COVID-19 pandemic (Basu et al., 2021). A meta-analysis involving people at high risk for COVID-19 infection, namely medical workers, also showed that participants in Asian countries had a low prevalence of adverse psychological symptoms during the pandemic (Olava et al., 2021). Given that the severity of the COVID-19 pandemic and control measures differed among countries, more international studies are needed to examine region-specific effects of the COVID-19 pandemic on postpartum psychological health. Our subgroup analyses showed that the pooled prevalence of postpartum psychological symptoms was higher in studies that used online surveys, which indicated that the survey method may influence the performance on self-reported scales of psychological health.

To our knowledge, this study is the first to pool the prevalence of postpartum depressive, anxiety, stress, and PTSD symptoms during the COVID-19 pandemic and estimate the effects of the pandemic on the psychological health of postpartum women. In addition, postpartum women that were >6 weeks after delivery, younger than 35 years, with a low income, with less education, and that used formula feeding were more susceptible to the effects of the COVID-19 pandemic on psychological health. These findings could provide comprehensive new evidence to prevent postpartum psychological disorders during the COVID-19 pandemic. Our study had some limitations. First, significant but



**Fig. 6.** Subgroup analysis of the odds ratio of the COVID-19 pandemic for postpartum depressive symptoms by (A) continent, (B) study design, (C) assessment scale, (D) time after delivery, (E) survey method, (F) study quality. Abbreviations: CES-D-10, the 10-item Center for Epidemiological Studies Depression scale; EPDS, the Edinburgh Postnatal Depression scale.



Fig. 7. Funnel plot for the prevalence of postpartum depressive symptoms.

inevitable heterogeneities were found in some analyses. To reduce the effect of heterogeneities on the meta-analyses, random-effect modelling and subgroup analyses were performed to estimate the pooled prevalence and ORs for postpartum psychological symptoms. Second, most included studies were cross-sectional or non-concurrent case-control design without multivariate analyses, and <50 % were assessed as high quality. The main reasons for non-ideal quality of original studies were consecutive subjects, evaluators masked, missing data, and follow-up period. Although we found that the risk for psychological symptoms in postpartum women was significantly increased during the COVID-19 pandemic, we cannot conclude that the COVID-19 pandemic was the main cause of postpartum psychological disorders. However, subgroup analyses revealed that the prevalence and risk for postpartum psychological symptoms in high-quality or panel studies were consistent with the pooled analyses. More prospective studies are needed to confirm the

effect of the COVID-19 pandemic on postpartum psychological health. Third, the prevalence of postpartum insomnia during the COVID-19 pandemic was unable to be pooled because it was reported by only one study. More studies could focus on postpartum sleep disorders during the COVID-19 pandemic to clarify this point. Fourth, most online-survey-based studies were performed among women >6 weeks after delivery who experienced higher risk for postpartum psychological symptoms during the COVID-19 pandemic, indicating that potential selection bias may exist in the original studies.

In conclusion, our study found that a significantly higher proportion of postpartum women suffered from symptoms of psychological disorders during the COVID-19 pandemic compared with before the pandemic. More attention and preventive measures should be adopted to improve psychological health in postpartum women, particularly for those >6 weeks after delivery, younger than 35 years, with a low income, with less education, and that use formula feeding.

#### Funding

This work was supported by the National Key Research and Development Program of China (2016YFC1000101).

#### CRediT authorship contribution statement

Wentao Yue and Chenghong Yin initiated and designed the research. Shen Gao, Shaofei Su and Enjie Zhang searched and identified literatures. Enjie Zhang, Ruixia Liu, Yue Zhang and Chengrong Wang performed data extraction. Jianhui Liu and Shuanghua Xie assessed the quality of included studies. Shen Gao and Shaofei Su performed metaanalyses. Shen Gao and Shaofei Su wrote the first draft of the manuscription. Wentao Yue and Chenghong Yin contributed to manuscript revision and supervision. All authors contributed to manuscript final version approval.

#### **Conflict of Interest**

All the authors declared no potential competing interests with respect to the research, authorship, and/or publication in this paper.

#### Acknowledgements

76 (Suppl. 4), 76-83.

No.

#### References

- Abdollahi, F., Zarghami, M., 2018. Effect of postpartum depression on women's mental and physical health four years after childbirth. East Mediterr. Health J. 24 (10), 1002–1009.
- Alshikh Ahmad, H., Alkhatib, A., Luo, J., 2021. Prevalence and risk factors of postpartum depression in the Middle East: a systematic review and meta-analysis. BMC Pregnancy Childbirth 21 (1), 542.
- An, R., Chen, X., Wu, Y., et al., 2021. A survey of postpartum depression and health care needs among Chinese postpartum women during the pandemic of COVID-19. Arch. Psychiatr. Nurs. 35 (2), 172–177.
- Ayaz, R., Hocaoğlu, M., Günay, T., et al., 2020. Anxiety and depression symptoms in the same pregnant women before and during the COVID-19 pandemic. J. Perinat. Med. 48 (9), 965–970.
- Basu, A., Kim, H.H., Basaldua, R., et al., 2021. A cross-national study of factors associated with women's perinatal mental health and wellbeing during the COVID-19 pandemic. PLoS One 16 (4), e0249780.
- Blettner, M., Sauerbrei, W., Schlehofer, B., et al., 1999. Traditional reviews, metaanalyses and pooled analyses in epidemiology. Int. J. Epidemiol. 28 (1), 1–9.
- Bo, H.X., Yang, Y., Chen, J., et al., 2020. Prevalence of depressive symptoms among pregnant and postpartum women in China during the COVID-19 pandemic. Psychosom. Med. 83 (4), 345–350.
- Boekhorst, M., Muskens, L., Hulsbosch, L.P., et al., 2021. The COVID-19 outbreak increases maternal stress during pregnancy, but not the risk for postpartum depression. Arch. Womens Ment. Health 24 (6), 1037–1043.

 Brooks, S.K., Weston, D., Greenberg, N., 2020. Psychological impact of infectious disease outbreaks on pregnant women: rapid evidence review. Public Health 189, 26–36.
 Cantwell, R., 2021. Mental disorder in pregnancy and the early postpartum. Anaesthesia

#### Journal of Affective Disorders 319 (2022) 99-111

- Ceulemans, M., Hompes, T., Foulon, V., 2020. Mental health status of pregnant and breastfeeding women during the COVID-19 pandemic: a call for action. Int. J. Gynaecol. Obstet. 151 (1), 146–147.
- Ceulemans, M., Foulon, V., Ngo, E., et al., 2021. Mental health status of pregnant and breastfeeding women during the COVID-19 pandemic-A multinational crosssectional study. Acta Obstet. Gynecol. Scand. 100 (7), 1219–1229.
- Chaves, C., Marchena, C., Palacios, B., et al., 2022. Effects of the COVID-19 pandemic on perinatal mental health in Spain: positive and negative outcomes. Women Birth. 35 (3), 254–261.
- Chmielewska, B., Barratt, I., Townsend, R., et al., 2021. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and metaanalysis. Lancet Glob. Health 9 (6), e759–e772.
- Chrzan-Detkoś, M., Walczak-Kozłowska, T., Lipowska, M., 2021. The need for additional mental health support for women in the postpartum period in the times of epidemic crisis. BMC Pregnancy Childbirth 21 (1), 114.
- Cooper, P.J., Campbell, E.A., Day, A., et al., 1988. Non-psychotic psychiatric disorder after childbirth. A prospective study of prevalence, incidence, course and nature. Br. J. Psychiatry 152, 799–806.
- Dennis, C.L., Falah-Hassani, K., Shiri, R., 2017. Prevalence of antenatal and postnatal anxiety: systematic review and meta-analysis. Br. J. Psychiatry 210 (5), 315–323.
- DerSimonian, R., Laird, N., 1986. Meta-analysis in clinical trials. Control. Clin. Trials 7 (3), 177–188.
- Dib, S., Rougeaux, E., Vázquez-Vázquez, A., et al., 2020. Maternal mental health and coping during the COVID-19 lockdown in the UK: data from the COVID-19 new mum study. Int. J. Gynaecol. Obstet. 151 (3), 407–414.
- Fallon, V., Davies, S.M., Silverio, S.A., et al., 2021. Psychosocial experiences of postnatal women during the COVID-19 pandemic. A UK-wide study of prevalence rates and risk factors for clinically relevant depression and anxiety. J. Psychiatr. Res. 136, 157–166.
- Fan, S., Guan, J., Cao, L., et al., 2021. Psychological effects caused by COVID-19 pandemic on pregnant women: a systematic review with meta-analysis. Asian J. Psychiatr. 56, 102533.
- Farewell, C.V., Jewell, J., Walls, J., et al., 2020. A mixed-methods pilot study of perinatal risk and resilience during COVID-19. J. Prim. Care Community Health 11, 2150132720944074.
- Feldman, R., Granat, A., Pariente, C., et al., 2009. Maternal depression and anxiety across the postpartum year and infant social engagement, fear regulation, and stress reactivity. J. Am. Acad. Child Adolesc. Psychiatry 48 (9), 919–927.
- Fernandes, D.V., Canavarro, M.C., Moreira, H., 2021. Postpartum during COVID-19 pandemic: Portuguese mothers' mental health, mindful parenting, and mother-infant bonding. J. Clin. Psychol. 77 (9), 1997–2010.
- Guintivano, J., Manuck, T., Meltzer-Brody, S., 2018. Predictors of postpartum depression: a comprehensive review of the last decade of evidence. Clin. Obstet. Gynecol. 61 (3), 591–603.
- Guvenc, G., Yesilcinar, İ., Ozkececi, F., et al., 2021. Anxiety, depression, and knowledge level in postpartum women during the COVID-19 pandemic. Perspect. Psychiatr. Care 57 (3), 1449–1458.
- Haga, S.M., Ulleberg, P., Slinning, K., et al., 2012. A longitudinal study of postpartum depressive symptoms: multilevel growth curve analyses of emotion regulation strategies, breastfeeding self-efficacy, and social support. Arch. Womens Ment. Health 15 (3), 175–184.
- Halligan, S.L., Murray, L., Martins, C., et al., 2007. Maternal depression and psychiatric outcomes in adolescent offspring: a 13-year longitudinal study. J. Affect. Disord. 97 (1–3), 145–154.
- Hamami, H., Sheiner, E., Wainstock, T., et al., 2020. The association between delivery during the COVID-19 pandemic and immediate postpartum maternal cognitive function. J. Clin. Med. 9 (11), 3727.
- Hessami, K., Romanelli, C., Chiurazzi, M., et al., 2020. COVID-19 pandemic and maternal mental health: a systematic review and meta-analysis. J. Matern. Fetal Neonatal Med. 1–8.
- Higgins, J.P., Thompson, S.G., Deeks, J.J., et al., 2003. Measuring inconsistency in metaanalyses. BMJ 327 (7414), 557–560.
- Hiiragi, K., Obata, S., Misumi, T., et al., 2021. Psychological stress associated with the COVID-19 pandemic in postpartum women in Yokohama, Japan. J. Obstet. Gynaecol. Res. 47 (6), 2126–2130.
- Howard, L.M., Molyneaux, E., Dennis, C.L., et al., 2014. Non-psychotic mental disorders in the perinatal period. Lancet 384 (9956), 1775–1788.
- Hui, P.W., Ma, G., Seto, M.T.Y., et al., 2021. Effect of COVID-19 on delivery plans and postnatal depression scores of pregnant women. Hong Kong Med. J. 27 (2), 113–117.
- Jafree, S.R., Momina, A., Muazzam, A., et al., 2021. Factors affecting delivery health service satisfaction of women and fear of COVID- 19: implications for maternal and child health in Pakistan. Matern. Child Health J. 25 (6), 881–891.
- Kessler, R.C., Amminger, G.P., Aguilar-Gaxiola, S., et al., 2007. Age of onset of mental disorders: a review of recent literature. Curr.Opin. Psychiatry 20 (4), 359–364.
- Kolakowsky-Hayner, S.A., Goldin, Y., Kingsley, K., et al., 2021. Psychosocial impacts of the COVID-19 quarantine: a study of gender differences in 59 countries. Medicina (Kaunas) 57 (8), 789.
- Krishnamoorthy, Y., Nagarajan, R., Saya, G.K., et al., 2020. Prevalence of psychological morbidities among general population, healthcare workers and COVID-19 patients amidst the COVID-19 pandemic: a systematic review and meta-analysis. Psychiatry Res. 293, 113382.
- Lebel, C., Walton, M., Letourneau, N., et al., 2016. Prepartum and postpartum maternal depressive symptoms are related to Children's brain structure in preschool. Biol. Psychiatry 80 (11), 859–868.

#### S. Gao et al.

Letourneau, N.L., Dennis, C.L., Benzies, K., et al., 2012. Postpartum depression is a family affair: addressing the impact on mothers, fathers, and children. Issues Ment. Health Nurs. 33 (7), 445–457.

- Li, X., Lu, P., Hu, L., et al., 2020. Factors associated with mental health results among workers with income losses exposed to COVID-19 in China. Int. J. Environ. Res. Public Health 17 (15), 5627.
- Li, S., Wang, Y., Xue, J., et al., 2020. The impact of COVID-19 epidemic declaration on psychological consequences: a study on active Weibo users. Int. J. Environ. Res. Public Health 17 (6), 2032.
- Li, C., Huo, L., Wang, R., et al., 2021. The prevalence and risk factors of depression in prenatal and postnatal women in China with the outbreak of Corona virus disease 2019. J. Affect. Disord. 282, 1203–1209.
- Liang, P., Wang, Y., Shi, S., et al., 2020. Prevalence and factors associated with postpartum depression during the COVID-19 pandemic among women in Guangzhou, China: a cross-sectional study. BMC Psychiatry 20 (1), 557.
- Liu, X., Kakade, M., Fuller, C.J., et al., 2012. Depression after exposure to stressful events: lessons learned from the severe acute respiratory syndrome epidemic. Compr. Psychiatry 53 (1), 15–23.
- Liu, C.H., Erdei, C., Mittal, L., 2021. Risk factors for depression, anxiety, and PTSD symptoms in perinatal women during the COVID-19 pandemic. Psychiatry Res. 295, 113552.
- Lorentz, M.S., Chagas, L.B., Perez, A.V., et al., 2020. Correlation between depressive symptoms and sexual dysfunction in postpartum women during the COVID-19 pandemic. Eur. J. Obstet. Gynecol. Reprod. Biol. 258, 162–167.
- Loret de Mola, C., Martins-Silva, T., Carpena, M.X., et al., 2021. Maternal mental health before and during the COVID-19 pandemic in the 2019 Rio Grande birth cohort. Br. J. Psychiatry 43 (4), 402–406.
- Mariño-Narvaez, C., Puertas-Gonzalez, J.A., Romero-Gonzalez, B., et al., 2021. Giving birth during the COVID-19 pandemic: the impact on birth satisfaction and postpartum depression. Int. J. Gynaecol. Obstet. 153 (1), 83–88.
- Masters, G.A., Asipenko, E., Bergman, A.L., et al., 2021. Impact of the COVID-19 pandemic on mental health, access to care, and health disparities in the perinatal period. J. Psychiatr. Res. 137, 126–130.
- Mayopoulos, G.A., Ein-Dor, T., Dishy, G.A., et al., 2021. COVID-19 is associated with traumatic childbirth and subsequent mother-infant bonding problems. J. Affect. Disord. 282, 122–125.
- McFarland, M.J., McFarland, C.A.S., Hill, T.D., et al., 2021. Postpartum depressive symptoms during the beginning of the COVID-19 pandemic: an examination of population birth data from Central New Jersey. Matern. Child Health J. 25 (3), 353–359.
- Molgora, S., Accordini, M., 2020. Motherhood in the time of coronavirus: the impact of the pandemic emergency on expectant and postpartum women's psychological wellbeing. Front. Psychol. 11, 567155.
- Olaya, B., Perez-Moreno, M., Bueno-Notivol, J., et al., 2021. Prevalence of depression among healthcare workers during the COVID-19 outbreak: a systematic review and meta-analysis. J. Clin. Med. 10 (15), 3406.
- Ollivier, R., Aston, D.M., Price, D.S., et al., 2021. Mental health & parental concerns during COVID-19: the experiences of new mothers amidst social isolation. Midwifery 94, 102902.
- Oskovi-Kaplan, Z.A., Buyuk, G.N., Ozgu-Erdinc, A.S., et al., 2021. The effect of COVID-19 pandemic and social restrictions on depression rates and maternal attachment in immediate postpartum women: a preliminary study. Psychiatr. O. 92 (2), 675–682.
- Ostacoli, L., Cosma, S., Bevilacqua, F., et al., 2020. Psychosocial factors associated with postpartum psychological distress during the Covid-19 pandemic: a cross-sectional study. BMC Pregnancy Childbirth 20 (1), 703.
- Pariente, G., Wissotzky Broder, O., Sheiner, E., et al., 2020. Risk for probable postpartum depression among women during the COVID-19 pandemic. Arch. Womens Ment. Health 23 (6), 767–773.
- Payne, J.L., Maguire, J., 2019. Pathophysiological mechanisms implicated in postpartum depression. Front. Neuroendocrinol. 52, 165–180.
- Perzow, S.E.D., Hennessey, E.P., Hoffman, M.C., et al., 2021. Mental health of pregnant and postpartum women in response to the COVID-19 pandemic. J. Affect. Disord. Rep. 4, 100123.
- Phillips, N., 2021. The coronavirus is here to stay here's what that means. Nature 590 (7846), 382–384.
- Racine, N., Hetherington, E., McArthur, B.A., et al., 2021. Maternal depressive and anxiety symptoms before and during the COVID-19 pandemic in Canada: a longitudinal analysis. Lancet Psychiatry 8 (5), 405–415.

- Rostom, A., Dubé, C., Cranney, A., 2004. Celiac disease. Sep. Available at:. Agency for Healthcare Research and Quality (US), Rockville (MD) https://www.ncbi.nlm.nih. gov/books/NBK35156/.
- Sangsawang, B., Deoisres, W., Hengudomsub, P., et al., 2022. Effectiveness of psychosocial support provided by midwives and family on preventing postpartum depression among first-time adolescent mothers at 3-month follow-up: a randomised controlled trial. J. Clin. Nurs. 31 (5–6), 689–702.
- Shayganfard, M., Mahdavi, F., Haghighi, M., et al., 2020. Health anxiety predicts postponing or cancelling routine medical health care appointments among women in perinatal stage during the Covid-19 lockdown. Int. J. Environ. Res. Public Health 17 (21), 8272.
- Shorey, S.Y., Ng, E.D., Chee, C.Y.I., 2021. Anxiety and depressive symptoms of women in the perinatal period during the COVID-19 pandemic: A systematic review and metaanalysis. Scand. J. Public Health 49 (7), 730–740.
- Silverman, M.E., Burgos, L., Rodriguez, Z.I., et al., 2020. Postpartum mood among universally screened high and low socioeconomic status patients during COVID-19 social restrictions in New York City. Sci. Rep. 10 (1), 22380.
- Spinola, O., Liotti, M., Speranza, A.M., et al., 2020. Effects of COVID-19 epidemic lockdown on postpartum depressive symptoms in a sample of Italian mothers. Front. Psychiatry 11, 589916.
- Stein, A., Pearson, R.M., Goodman, S.H., et al., 2014. Effects of perinatal mental disorders on the fetus and child. Lancet 384 (9956), 1800–1819.
- Stepowicz, A., Wencka, B., Bieńkiewicz, J., et al., 2020. Stress and anxiety levels in pregnant and post-partum women during the COVID-19 pandemic. Int. J. Environ. Res. Public Health 17 (24).
- Stojanov, J., Stankovic, M., Zikic, O., et al., 2021. The risk for nonpsychotic postpartum mood and anxiety disorders during the COVID-19 pandemic. Int. J. Psychiatry Med. 56 (4), 228–239.
- Stroup, D.F., Berlin, J.A., Morton, S.C., et al., 2000. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283 (15), 2008–2012.
- Suárez-Rico, B.V., Estrada-Gutierrez, G., Sánchez-Martínez, M., et al., 2021. Prevalence of depression, anxiety, and perceived stress in postpartum Mexican women during the COVID-19 lockdown. Int. J. Environ. Res. Public Health 18 (9), 4627.
- Sun, F., Zhu, J., Tao, H., et al., 2020. A systematic review involving 11,187 participants evaluating the impact of COVID-19 on anxiety and depression in pregnant women. J. Psychosom. Obstet. Gynaecol. 1–9.
- Sun, G., Wang, Q., Lin, Y., et al., 2020. Perinatal depression of exposed maternal women in the COVID-19 pandemic in Wuhan China. Front. Psychiatry 11, 551812.
- Suzuki, S., 2022. Psychological status of postpartum women under the COVID-19 pandemic in Japan. J. Matern. Fetal Neonatal Med. 35 (9), 1798–1800.
- Vesga-Lopez, O., Blanco, C., Keyes, K., et al., 2008. Psychiatric disorders in pregnant and postpartum women in the United States. Arch. Gen. Psychiatry 65 (7), 805–815.
- Wang, J., Zhou, Y., Qian, W., et al., 2021. Maternal insomnia during the COVID-19 pandemic: associations with depression and anxiety. Soc. Psychiatry Psychiatr. Epidemiol. 1–9.
- Wells, G., Shea, B., O'Connell, D.. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri. ca/programs/clinical\_epidemiology/nosgen.pdf.
- Woolhouse, H., Gartland, D., Mensah, F., et al., 2015. Maternal depression from early pregnancy to 4 years postpartum in a prospective pregnancy cohort study: implications for primary health care. BJOG 122 (3), 312–321.
- World Health Organization. WHO Coronavirus (COVID-19) dashboard. Available at: https://www.covid19.who.int/.
- Xue, A., Oros, V., Marca-Ghaemmaghami, P., et al., 2021. New parents experienced lower parenting self-efficacy during the COVID-19 pandemic lockdown. Children (Basel) 8 (2).
- Yan, H., Ding, Y., Guo, W., 2020. Mental health of pregnant and postpartum women during the Coronavirus Disease 2019 pandemic: a systematic review and metaanalysis. Front. Psychol. 11, 617001.
- Yuan, R., Xu, Q.H., Xia, C.C., et al., 2020. Psychological status of parents of hospitalized children during the COVID-19 epidemic in China. Psychiatry Res. 288, 112953.
- Zanardo, V., Manghina, V., Giliberti, L., et al., 2020. Psychological impact of COVID-19 quarantine measures in northeastern Italy on mothers in the immediate postpartum period. Int. J. Gynaecol. Obstet. 150 (2), 184–188.
- Zeng, X., Li, W., Sun, H., et al., 2020. Mental health outcomes in perinatal women during the remission phase of COVID-19 in China. Front. Psychiatry 11, 571876.
- Zhao, X.H., Zhang, Z.H., 2020. Risk factors for postpartum depression: an evidence-based systematic review of systematic reviews and meta-analyses. Asian J. Psychiatr. 53, 102353.